- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00795860
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise
October 12, 2017 updated by: Jeffrey F Horowitz, University of Michigan
Clearly the effects of diet and exercise are beneficial for obese persons, but the underlying mechanisms for the improvements in metabolic health are not completely clear.
Although mounting evidence suggests that alterations in lipid metabolism in persons with abdominal obesity are associated with a several medical complications, including diabetes, little is known about the factors responsible for this effect.
The project in this application is designed to examine how the addition of endurance exercise training to a weight-loss program alters whole-body fatty acid availability, uptake, and oxidation as well as the expression of cellular factors that regulate these processes.
In addition, we will evaluate whether these alterations are associated with improvements in insulin sensitivity.
In the end, these experiments will provide insight into the cellular and whole-body adaptations in fatty acid metabolism in response to weight-loss and exercise training that may lead to enhancement of insulin sensitivity.
Identifying relationships between gene expression, whole-body fatty acid metabolism and clinical outcome measurements, such as insulin sensitivity, may lead to improvements in the therapeutic and/or the preventative approach to obesity and its co-morbidities.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Despite robust findings emphasizing the importance of weight-loss and exercise for the prevention and management of insulin resistance and Type 2 diabetes, the mechanisms responsible for the improvements in metabolic health are not completely understood.
Mounting evidence suggests that abnormalities in fatty acid metabolism in persons with abdominal obesity are associated with insulin resistance.
Alterations in fatty acid mobilization and oxidation may be primary adaptations responsible for the improvements in metabolic health after weight-loss and endurance exercise training.
We hypothesize that a disparity between muscle fatty acid uptake and oxidation is regulated by the expression of genes and proteins that participate in intracellular transport, trafficking, and metabolism of fatty acids.
We believe that alterations in the expression of these factors in response to weight-loss and endurance exercise training will underlie changes in the non-oxidative disposal of fatty acids, and thereby improve insulin sensitivity.
We will determine the effects of weight-loss and exercise training on whole-body fatty acid mobilization and oxidation and the expression of factors that regulate these processes in skeletal muscle.
In addition, we will evaluate how these alterations are associated with improvements in insulin sensitivity.
These studies will provide insight into how cellular alterations with weight-loss and exercise training and the accompanying changes in whole-body fatty acid metabolism may lead to improvements in metabolic health.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female
- Age = 18-45
- Premenopausal
- Body mass index ≥ 30 kg/m2
- Waist circumference ≥ 100 cm
Exclusion Criteria:
- Evidence of metabolic or cardiovascular disease
- Pregnancy
- Allergies to soybeans or eggs
- Hyperlipidemia (fasting plasma triglyceride concentration > 125 mg/dl)
- Hematocrit < 34%
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Weight loss - diet only
|
Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight.
After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed.
Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
|
Experimental: Weight loss plus exercise
|
Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight.
Exercise training consists of stationary bicycle exercise.
the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate.
3 of the 4 exercise session each week are supervised by an Exercise physiologist.
After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed.
Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Insulin sensitivity
Time Frame: before and after 12% weight loss (3-6 months)
|
before and after 12% weight loss (3-6 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of fatty acid mobilization in plasma
Time Frame: Before and after 12% weight loss (3-6 months)
|
Before and after 12% weight loss (3-6 months)
|
Abundance and activity of Pro-inflammatory factors in skeletal muscle
Time Frame: Before and after 12% weight loss (3-6 months)
|
Before and after 12% weight loss (3-6 months)
|
whole body and skeletal muscle oxidative capacity
Time Frame: Before and after 12% weight loss (3-6 months)
|
Before and after 12% weight loss (3-6 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey Horowitz, PhD, University of Michigan
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2003
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
November 20, 2008
First Submitted That Met QC Criteria
November 20, 2008
First Posted (Estimate)
November 21, 2008
Study Record Updates
Last Update Posted (Actual)
October 16, 2017
Last Update Submitted That Met QC Criteria
October 12, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADA - 1-03-JF-10 (completed)
- ADA grant# 1-03-JF-10 (Other Grant/Funding Number: American Diabetes Association)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance and Type 2 Diabetes
-
Vanderbilt UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedInsulin Resistance and Type 2 Diabetes
-
China Medical University HospitalCompletedType 2 Diabetes Mellitus With Features of Insulin ResistanceTaiwan
-
Hospital General Universitario ElcheCompletedDiabetes Mellitus Type 2 in Obese | Type 2 Diabetes Mellitus With Features of Insulin ResistanceSpain
-
National Center for Complementary and Integrative...Completed
-
Amsterdam UMC, location VUmcAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)CompletedType 2 Diabetes Mellitus | Insulin Sensitivity/ResistanceNetherlands
-
Postgraduate Institute of Medical Education and...UnknownType 2 Diabetes Mellitus | Insulin Sensitivity/ResistanceIndia
-
Charles University, Czech RepublicCompletedType 2 Diabetes Mellitus With Features of Insulin ResistanceCzech Republic
-
University of MinnesotaEli Lilly and CompanyCompletedInsulin Resistance | Type 2 Diabetes | High Insulin RequirementsUnited States
-
Ain Shams UniversityCompleted
-
German Diabetes CenterCompleted
Clinical Trials on Weight loss - diet only
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Overweight | Type 2 Diabetes | PrediabetesUnited States
-
University of Alabama at BirminghamCompletedCancer | Weight LossUnited States
-
Colorado State UniversityCompleted
-
Centro Studi GisedAzienda Ospedaliero-Universitaria di ModenaCompleted
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
University of Tennessee Health Science CenterRecruiting
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedHypertension | Diabetes | Insulin ResistanceUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingObesity | Muscle Weakness | Insulin Resistance | Adiposity | Insulin SensitivityUnited States
-
Hacettepe UniversityRecruitingObesity | Polymorphism, Restriction Fragment LengthTurkey